Dr Gregory J Tiesi and Team of Cancer Experts Implant First Targeted Liver Tumor Treatment Pumps in Patients

What You Need To Know

• A team of surgical experts at Jersey Shore University Medical Center, led by Gregory J. Tiesi, M.D., FACS, FSSO, are among the first in New Jersey to implant hepatic artery infusion pumps in patients.
• The Intera 3000 Pump enables highly pinpointed and concentrated Hepatic Artery Infusion (HAI) therapy for the treatment of cancers within the liver, including intrahepatic cholangiocarcinoma (IHCC, bile duct cancer) and colorectal cancer liver metastases, without the negative side effects seen with systemic chemotherapy.

Colorectal cancer is the third most common cancer diagnosed in adults each year in the U.S., excluding skin cancer. The liver is the most frequent site of metastatic disease, with at least 25 percent of patients developing colorectal liver metastases during the course of their illness. IHCC is the second most common primary cancer of the liver. The palm-sized pump is surgically implanted in the abdomen and designed to deliver a continuous flow of chemotherapy directly to the hepatic artery that feeds tumors in the liver. Individuals receiving HAI therapy continue their normal daily activities outside of a hospital with minimal disruption to their lives.

“This state-of-the-art technology provides a highly pinpointed and concentrated treatment option for patients with advanced primary liver cancers like IHCC, which have a poor prognosis and are hard to treat and colorectal cancer liver metastases, without the negative side effects or toxicities that accompany chemotherapy like when it is delivered through a vein to the whole body." -- Dr. Gregory J. Tiesi